Literature DB >> 21144106

Ameliorative effects of konjac glucomannan on human faecal β-glucuronidase activity, secondary bile acid levels and faecal water toxicity towards Caco-2 cells.

Wen-Tzu Wu1, Han-Chung Cheng, Hsiao-Ling Chen.   

Abstract

Konjac glucomannan (KGM) has been shown to increase human colon microbial ecology and reduce faecal toxicity in mice. The main goal of the present study was to assess the effects of a KGM supplement into a low-fibre diet on precancerous markers of colon cancer in a double-blind, placebo- and diet-controlled study. Adult volunteers consumed defined diets supplemented with konjac (4·5 g/d) or placebo (maize starch) for 4 weeks. Stools collected before and at the end of the supplementation were analysed for β-glucosidase, β-galactosidase and β-glucuronidase activities, microflora and bile acids. Faecal water was co-incubated with Caco-2 cells, a model of human colonocytes, to determine the cytotoxicity and DNA-damaging effect as assessed by the comet assay. The results indicated that the KGM supplement significantly decreased faecal β-glucuronidase activity by 25·6 (se 7·8) % and faecal secondary bile acid level by 42·4 (se 11·8) %. In contrast, consuming the defined diet supplemented with placebo for 4 weeks did not improve these determinants. The KGM-supplemented diet, but not the placebo diet, significantly increased the survival rate (%) of Caco-2 cells co-incubated with faecal water for 1 and 3 h, respectively. In addition, KGM significantly reduced the DNA damage induced by the faecal water alone or in combination with H2O2. The faecal bifidobacteria and lactobacilli levels increased only with the KGM-supplemented diet. Therefore, we conclude that supplementation of KGM into a low-fibre diet improved the faecal microbial ecology and metabolites, which may contribute to the reduced toxicity of faecal water and precancerous risk factors of human colon cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21144106     DOI: 10.1017/S0007114510004009

Source DB:  PubMed          Journal:  Br J Nutr        ISSN: 0007-1145            Impact factor:   3.718


  7 in total

Review 1.  Bile acid dysregulation, gut dysbiosis, and gastrointestinal cancer.

Authors:  Jessica Tsuei; Thinh Chau; David Mills; Yu-Jui Yvonne Wan
Journal:  Exp Biol Med (Maywood)       Date:  2014-06-20

Review 2.  Towards microbial fermentation metabolites as markers for health benefits of prebiotics.

Authors:  Kristin A Verbeke; Alan R Boobis; Alessandro Chiodini; Christine A Edwards; Anne Franck; Michiel Kleerebezem; Arjen Nauta; Jeroen Raes; Eric A F van Tol; Kieran M Tuohy
Journal:  Nutr Res Rev       Date:  2015-06       Impact factor: 7.800

3.  The role of intestinal microbiota in development of irinotecan toxicity and in toxicity reduction through dietary fibres in rats.

Authors:  Xiaoxi B Lin; Arazm Farhangfar; Rosica Valcheva; Michael B Sawyer; Levinus Dieleman; Andreas Schieber; Michael G Gänzle; Vickie Baracos
Journal:  PLoS One       Date:  2014-01-14       Impact factor: 3.240

Review 4.  Role of intestinal flora in colorectal cancer from the metabolite perspective: a systematic review.

Authors:  Shuwen Han; Jianlan Gao; Qing Zhou; Shanshan Liu; Caixia Wen; Xi Yang
Journal:  Cancer Manag Res       Date:  2018-01-31       Impact factor: 3.989

5.  Evaluation of white sweet potato tube-feeding formula in elderly diabetic patients: a randomized controlled trial.

Authors:  Chiao-Ming Chen; Chun-Kuang Shih; Yi-Jing Su; Kuan-Un Cheang; Shu-Fang Lo; Sing-Chung Li
Journal:  Nutr Metab (Lond)       Date:  2019-10-16       Impact factor: 4.169

Review 6.  Review on Modification of Glucomannan as an Excipient in Solid Dosage Forms.

Authors:  Nuur Aanisah; Yoga W Wardhana; Anis Y Chaerunisaa; Arif Budiman
Journal:  Polymers (Basel)       Date:  2022-06-23       Impact factor: 4.967

Review 7.  A Systematic Review Exploring the Anticancer Activity and Mechanisms of Glucomannan.

Authors:  Jun-Yi Li; Fei Sun; Hai-Feng Zhou; Jia Yang; Cong Huang; Heng Fan
Journal:  Front Pharmacol       Date:  2019-08-23       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.